New hope for tough breast cancer: targeted pill after chemo shows promise in large trial

This study tests whether taking the oral drug everolimus after standard chemotherapy can help prevent breast cancer from coming back in people with a specific subtype of triple-negative breast cancer called LAR. The trial will enroll 904 women who have had surgery for early-stage disease. Participants will be randomly assigned to receive either standard chemotherapy alone or chemotherapy followed by everolimus, and researchers will track how many remain cancer-free for three years.